Talquetamab, a GPRC5D×CD3 bispecific antibody, in Chinese patients with relapsed/refractory multiple myeloma: efficacy and safety from the phase 1/2 MonumenTAL-1 study

Gang An, Jie Jin, Zhen Cai, Hongmei Jing, Chengcheng Fu, Pengcheng He, Zhongjun Xia, Rui Liu, Liang Li, Xue Gai, Hong Zhang, Dian Zhu, Xinchao Luo, Binbin Sun, Hongmei Xu, Longen Zhou, Michela Campagna, Tara J. Masterson, Bonnie W. Lau, Thomas Renaud, Christoph Heuck, Indrajeet Singh, Deeksha Vishwamitra, Lugui Qiu

Open source

DOI: 10.3324/haematol.2025.287334
Published: 2025-10-09
Container: Haematologica
Publisher: Ferrata Storti Foundation (Haematologica)
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.3324/haematol.2025.287334,
  title = {Talquetamab, a GPRC5D×CD3 bispecific antibody, in Chinese patients with relapsed/refractory multiple myeloma: efficacy and safety from the phase 1/2 MonumenTAL-1 study},
  author = {Gang An and Jie Jin and Zhen Cai and Hongmei Jing and Chengcheng Fu and Pengcheng He and Zhongjun Xia and Rui Liu and Liang Li and Xue Gai and Hong Zhang and Dian Zhu and Xinchao Luo and Binbin Sun and Hongmei Xu and Longen Zhou and Michela Campagna and Tara J. Masterson and Bonnie W. Lau and Thomas Renaud and Christoph Heuck and Indrajeet Singh and Deeksha Vishwamitra and Lugui Qiu},
  year = {2025},
  journal = {Haematologica},
  doi = {10.3324/haematol.2025.287334},
  url = {https://doi.org/10.3324/haematol.2025.287334}
}

RIS

TY  - JOUR
TI  - Talquetamab, a GPRC5D×CD3 bispecific antibody, in Chinese patients with relapsed/refractory multiple myeloma: efficacy and safety from the phase 1/2 MonumenTAL-1 study
AU  - Gang An
AU  - Jie Jin
AU  - Zhen Cai
AU  - Hongmei Jing
AU  - Chengcheng Fu
AU  - Pengcheng He
AU  - Zhongjun Xia
AU  - Rui Liu
AU  - Liang Li
AU  - Xue Gai
AU  - Hong Zhang
AU  - Dian Zhu
AU  - Xinchao Luo
AU  - Binbin Sun
AU  - Hongmei Xu
AU  - Longen Zhou
AU  - Michela Campagna
AU  - Tara J. Masterson
AU  - Bonnie W. Lau
AU  - Thomas Renaud
AU  - Christoph Heuck
AU  - Indrajeet Singh
AU  - Deeksha Vishwamitra
AU  - Lugui Qiu
PY  - 2025
JO  - Haematologica
DO  - 10.3324/haematol.2025.287334
UR  - https://doi.org/10.3324/haematol.2025.287334
ER  -

APA

An, G., Jin, J., Cai, Z., Jing, H., Fu, C., He, P., Xia, Z., Liu, R., Li, L., Gai, X., Zhang, H., Zhu, D., Luo, X., Sun, B., Xu, H., Zhou, L., Campagna, M., Masterson, T. J., Lau, B. W., Renaud, T., Heuck, C., Singh, I., Vishwamitra, D., & Qiu, L. (2025). Talquetamab, a GPRC5D×CD3 bispecific antibody, in Chinese patients with relapsed/refractory multiple myeloma: efficacy and safety from the phase 1/2 MonumenTAL-1 study. Haematologica. https://doi.org/10.3324/haematol.2025.287334

Source records

crossref · retrieved 2026-09-26T03:35:14.606Z